SRR15030845
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.610
- FATTY_ACID_METABOLISM+0.600
- XENOBIOTIC_METABOLISM+0.600
- OXIDATIVE_PHOSPHORYLATION+0.560
- ADIPOGENESIS+0.510
- CHOLESTEROL_HOMEOSTASIS+0.500
- PEROXISOME+0.430
- COAGULATION+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.420
- ANDROGEN_RESPONSE+0.320
Top 10 suppressed
- E2F_TARGETS-0.540
- G2M_CHECKPOINT-0.490
- WNT_BETA_CATENIN_SIGNALING-0.420
- MITOTIC_SPINDLE-0.330
- MYC_TARGETS_V2-0.250
- HEDGEHOG_SIGNALING-0.230
- SPERMATOGENESIS-0.200
- MYC_TARGETS_V1-0.190
- TNFA_SIGNALING_VIA_NFKB-0.170
- KRAS_SIGNALING_DN-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR15030885 | — | — | 0.912 |
| 2 | SRR15030860 | — | — | 0.906 |
| 3 | SRR15030850 | — | — | 0.900 |
| 4 | SRR4195657 | — | — | 0.876 |
| 5 | SRR4195645 | — | — | 0.873 |
| 6 | SRR4195672 | — | — | 0.868 |
| 7 | SRR8518149 | — | F | 0.844 |
| 8 | SRR975594 | — | — | 0.839 |
| 9 | BS_RWJZFTP9 | low-grade glioma | — | 0.824 |
| 10 | SRR11296843 | — | — | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.610 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.600 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.600 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.560 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.510 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.500 | Remibrutinib | — uncovered |
| PEROXISOME | 0.430 | Idelalisib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |